Magnetoliposomes containing calcium ferrite nanoparticles for applications in breast cancer therapy by Pereira, Daniela S.M. et al.
pharmaceutics
Article
Magnetoliposomes Containing Calcium Ferrite
Nanoparticles for Applications in Breast
Cancer Therapy
Daniela S. M. Pereira 1, Beatriz D. Cardoso 1, Ana Rita O. Rodrigues 1, Carlos O. Amorim 2,
Vítor S. Amaral 2, Bernardo G. Almeida 1, Maria-João R. P. Queiroz 3 , Olga Martinho 4,5 ,
Fátima Baltazar 4,5 , Ricardo C. Calhelha 6 , Isabel C. F. R. Ferreira 6 , Paulo J. G. Coutinho 1
and Elisabete M. S. Castanheira 1,*
1 Centre of Physics (CFUM), University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal;
daniela.s.pereira30@gmail.com (D.S.M.P.); beatrizdiascardoso94@gmail.com (B.D.C.);
ritarodrigues@fisica.uminho.pt (A.R.O.R.); bernardo@fisica.uminho.pt (B.G.A.);
pcoutinho@fisica.uminho.pt (P.J.G.C.)
2 Physics Department and CICECO, University of Aveiro, Campus de Santiago, 3810-193 Aveiro, Portugal;
amorim5@ua.pt (C.O.A.); vamaral@ua.pt (V.S.A.)
3 Centre of Chemistry, University of Minho, Campus de Gualtar, 4710-057 Braga, Portugal;
mjrpq@quimica.uminho.pt
4 Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, Campus de
Gualtar, 4710-057 Braga, Portugal; olgamartinho@med.uminho.pt (O.M.); fbaltazar@med.uminho.pt (F.B.)
5 ICVS/3B’s-PT Government Associate Laboratory, 4710-057 Braga/4806-909 Guimarães, Portugal
6 Mountain Research Centre, Polytechnic Institute of Bragança, Campus de Santa Apolónia,
5300-253 Bragança, Portugal; calhelha@ipb.pt (R.C.C.); iferreira@ipb.pt (I.C.F.R.F.)
* Correspondence: ecoutinho@fisica.uminho.pt; Tel.: +351-253-604-321
Received: 29 June 2019; Accepted: 11 September 2019; Published: 14 September 2019


Abstract: Magnetoliposomes containing calcium ferrite (CaFe2O4) nanoparticles were developed
and characterized for the first time. CaFe2O4 nanoparticles were covered by a lipid bilayer or
entrapped in liposomes forming, respectively, solid or aqueous magnetoliposomes as nanocarriers
for new antitumor drugs. The magnetic nanoparticles were characterized by UV/Visible absorption,
XRD, HR-TEM, and SQUID, exhibiting sizes of 5.2 ± 1.2 nm (from TEM) and a superparamagnetic
behavior. The magnetoliposomes were characterized by DLS and TEM. The incorporation of two new
potential antitumor drugs (thienopyridine derivatives) specifically active against breast cancer in these
nanosystems was investigated by fluorescence emission and anisotropy. Aqueous magnetoliposomes,
with hydrodynamic diameters around 130 nm, and solid magnetoliposomes with sizes of ca. 170 nm,
interact with biomembranes by fusion and are able to transport the antitumor drugs with generally
high encapsulation efficiencies (≥70%). These fully biocompatible drug-loaded magnetoliposomes
can be promising as therapeutic agents in future applications of combined breast cancer therapy.
Keywords: calcium ferrite nanoparticles; magnetoliposomes; new antitumor drugs; thienopyridine
derivatives; breast cancer therapy
1. Introduction
Cancer still represents a leading cause of morbidity and mortality worldwide, although new
treatments have improved the prognosis of cancer patients over the past years [1]. According to
the WHO, cancer was responsible for 8.8 million deaths in 2015, representing the second leading
cause of death [2]. Therefore, oncology is the first therapeutic area covered by nanomedicine [3].
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Considering the possibility of targeted chemotherapy, simultaneous hyperthermia and individualized
therapies, the so-called “magic bullets” are one of the most promising therapeutic approaches. These
“magic bullets” can selectively target cancerous tissues, as well as remotely release antitumor drugs
at optimal dosage. Numerous formulations based on different materials have been investigated to
design the “magic bullet” formulation with the best properties, including, for example, liposomes,
micelles, hydrogels, polymers, and magnetic nanoparticles [4]. The use of magnetic nanoparticles has
been widely investigated for their ability to target specific sites of interest, produce local heat, and
act as contrast agents [5]. However, toxicity issues have been raised, pointing to the need of fully
biocompatible nanomaterials [6]. Therefore, increasing attention has been given to the synthesis of
magnetic nanoparticles without transition metals on their constituents. Ions such as Ca2+ and Mg2+
have been proposed to substitute transition metals in the crystalline structure of ferrite nanoparticles,
as they may promote a higher biocompatibility [7]. Calcium ferrite nanoparticles have shown to
be biocompatible at concentrations below 250 mg/mL, in in vitro cytotoxicity tests on T-cell lines,
exhibiting enhanced cell viability when compared to other ferrites [8]. The high heating capacity of
calcium ferrite and calcium/magnesium ferrite nanoparticles also make them suitable for magnetic
hyperthermia [9,10].
Magneto-sensitive liposomes result from the incorporation of magnetic nanoparticles into
liposomes (aqueous magnetoliposomes) or from the covering of a nanoparticles cluster with a lipid
bilayer (solid or dry magnetoliposomes, SMLs). These magnetoliposomes can overcome individual
problems of liposomes and magnetic nanoparticles and, at the same time, gather the outstanding
properties of each in a single nanosystem [11]. Recently, magnetoliposomes based on several types of
superparamagnetic ferrite nanoparticles have been developed, namely iron oxide [12–17], manganese
ferrite [18,19], nickel ferrite [20], and magnesium ferrite nanoparticles [21].
Pursuing both high biocompatibility and heating capability, together with the ability to transport
antitumor drugs, in this work magnetoliposomes based on calcium ferrite nanoparticles were developed.
These systems were tested as nanocarriers for new potential antitumor drugs, diarylurea derivatives
of thienopyridine (Figure 1). Thienopyridine-based compounds have been described as promising
antitumoral agents and receptor tyrosine kinase inhibitors [22,23]. Moreover, a high antiproliferative
activity on human breast cancer cell lines, MCF-7 (hormone dependent breast adenocarcinoma)
and MDA-MB-231 (hormone independent, triple-negative breast cancer), was described for these
compounds [24], with very low growth inhibitory concentrations for 50% of cells, GI50 (Table 1).
Therefore, drug-loaded magnetoliposomes containing biocompatible calcium ferrite nanoparticles and
the antitumor compounds 1 or 2 can be promising nanosystems for breast cancer therapy.
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Figure 1. Structure of the 1-aryl-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]urea derivatives. 
Table 1. Growth inhibitory concentrations (GI50) of compounds 1 and 2 in breast cancer cell lines. 
GI50 (μM) [24] Compound 1 Compound 2 
MCF-7 1.2 ± 0.2 1.6 ± 0.3 
MDA-MB-231 5.0 ± 0.7 7.0 ± 0.8 
2. Materials and Methods 
Figure 1. Structure of the 1-aryl-3-[3-(thieno[3,2-b]pyridin-7-ylthio)phenyl]urea derivatives.
Table 1. Growth inhibitory concentrations (GI50) of compounds 1 and 2 in breast cancer cell lines.
GI50 (µM) [24] Compound 1 Compound 2
MCF-7 1.2 ± 0.2 1.6 ± 0.3
MDA-MB-231 5.0 ± 0.7 7.0 ± 0.8
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2. Materials and Methods
All the solutions were prepared using spectroscopic grade solvents and ultrapure water of Milli-Q
grade (MilliporeSigma, St. Louis, MO, USA).
2.1. Preparation of Calcium Ferrite Nanoparticles
Calcium ferrite (CaFe2O4) nanoparticles were synthesized in 2 mL aqueous solution, by the
co-precipitation method, as previously described by Hirazawa et al. [9]. First, a basic aqueous solution
of 50% NaOH was heated to 90 ◦C. Then, a mixture of solutions, 0.5 M calcium acetate dihydrate
and 1.0 M FeCl3·6H2O solution was added, drop by drop, to the previously warmed basic solution
under magnetic stirring. After two hours at 90 ◦C, calcium ferrite nanoparticles were formed. For
purification, the obtained sample was washed several times by centrifugation (14,000 g) and magnetic
decantation. Then, the samples were dried overnight at 60 ◦C. A calcination step at 600 ◦C was carried
out for 30 min [9]. At this temperature, the formation of brownmillerite (Ca2Fe2O5) is avoided [9].
2.2. Preparation of Magnetoliposomes
For magnetoliposomes preparation, the lipids l-α-phosphatidylcholine from egg yolk (Egg-PC),
and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), from Sigma-Aldrich (St. Louis, MO, USA),
were used in a final concentration of 1 mM. The ethanol injection method was employed to obtain
aqueous magnetoliposomes (AMLs) [25]. Accordingly, a 20 mM lipid solution in ethanol was
injected, under vigorous vortexing, to an aqueous dispersion of magnetic nanoparticles (with 4 mg/mL
concentration). After encapsulation, the ferrofluid was washed with water and purified by magnetic
decantation to remove all the non-encapsulated nanoparticles. Considering the strong difference in
maximum magnetization of magnetic nanoparticles and aqueous magnetoliposomes (as previously
reported [26,27]), due to the diamagnetic contribution of water, the aqueous magnetoliposomes are
not attracted to the magnet. Therefore, only non-encapsulated magnetic nanoparticles are separated
by this technique, keeping the magnetoliposomes in the supernatant phase. The lipid phase (in the
supernatant) remains unchanged upon decantation, the initial and final lipid concentrations being
the same.
For the preparation of solid magnetoliposomes, a method previously developed was used [19,20].
First, 10 µL of a solution of the synthesized magnetic nanoparticles (0.02 mg/mL) were ultrasonicated
for one minute at 189 W, and 3 mL of chloroform were added to the solution. Then,
immediately after vigorous agitation, 150 µL of a 20 mM methanolic solution of the lipid DPPC
(1,2-dipalmitoyl-sn-glycero-3-phosphocholine) were injected under vortexing, to form the first lipid
layer of the SMLs. To remove the lipid that was not attached to the nanoparticles surface, the particles
were washed twice by magnetic decantation with ultrapure water. The lipid bilayer was completed by
a new injection of 150 µL of 20 mM lipid methanolic solution, under vortexing, in 3 mL of aqueous
dispersion of the particles with the first lipid layer. The solid magnetoliposomes obtained were then
washed and purified with ultrapure water by magnetic decantation.
The antitumor thieno[3,2-b]pyridine derivatives 1 or 2 were incorporated into aqueous
magnetoliposomes by simultaneous injection of compound and lipid (co-injection method), in a
final compound concentration of 5 µM. Neat liposomes (without magnetic nanoparticles) with
encapsulated compounds were also prepared in the same manner. In solid magnetoliposomes, the
compound was incorporated by injection of an ethanolic solution (0.2 mM) immediately before the
formation of the second lipid layer.
2.3. Preparation of Giant Unilamellar Vesicles (GUVs)
GUVs of soybean lecithin (l-α-phosphatidylcholine from soybean), from Sigma-Aldrich (St. Louis,
MO, USA), were obtained by the thin film hydration method, as described by Tamba et al. [28,29]. A
lipid film of 100 µL of soybean lecithin solution (1 mM) was obtained by solvent evaporation under
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an ultrapure nitrogen stream, and 40 µL of water were added, followed by incubation at 45 ◦C for
30 min. Then, 3 mL of glucose aqueous solution (0.1 M) were added and the resulting solution was
again incubated at 37 ◦C for 2 h. After incubation, the GUVs suspension was centrifuged at 14,000 g
for 30 min at 20 ◦C, to remove multilamellar vesicles and lipid aggregates.
2.4. Spectroscopic Measurements
2.4.1. General Methods
Absorption spectra were performed in a Shimadzu UV-3600 Plus UV-vis-NIR (Shimadzu
Corporation, Kyoto, Japan) spectrophotometer. Fluorescence measurements were recorded using
a Horiba Fluorolog 3 spectrofluorimeter (HORIBA Jobin Yvon IBH Ltd., Glasgow, UK), equipped
with double monochromators in both excitation and emission, Glan-Thompson polarizers and a
temperature controlled cuvette holder. Fluorescence spectra were corrected for the instrumental
response of the system.
2.4.2. FRET Measurements
Förster resonance energy transfer (FRET) assays were used to confirm the formation of the
lipid bilayer in the solid magnetoliposomes containing CaFe2O4 nanoparticles. For that purpose,
the nitrobenzoxazole labeled lipid NBD-C12-HPC, 1-palmitoyl-2-{12-[(7-nitro-2-1,3-benzoxadiazol-
4-yl)-amino]hexanoyl}-sn-glycero-3-phosphocholine (from Avanti Polar Lipids, Alabaster, AL, USA)
was included in the first lipid layer, while the rhodamine B labeled lipid Rhodamine B-DOPE
(1,2-dioleoyl-sn-glycero-3-phosphoethanol-amine-N-lissamine rhodamine B sulfonyl (ammonium salt))
(from Avanti Polar Lipids, Alabaster, AL, USA) was included the second lipid layer (structures of the
labeled lipids in Figure 2).
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the ratio of the donor integrated fluorescence intensities in the presence of acceptor (FDA) and in the
absence of acceptor (FD) (Equation (1)) [30],
ΦRET = 1− FDAFD (1)
The distance between the donor and acceptor molecules was determined through the FRET
efficiency (Equation (2)),
r = R0
[
1−ΦRET
ΦRET
] 1
6
, (2)
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where R0 is the Förster radius (critical distance), that can be obtained by the spectral overlap, J(λ),
between the donor emission and the acceptor absorption, according to Equations (3) and (4) (with R0
in Å, λ in nm, εA(λ) in M−1·cm−1) [30],
R0 = 0.2108
[
k2Φ0Dn
−4 J(λ)
] 1
6 , (3)
J(λ) =
∫ ∞
0
ID(λ)εA(λ)λ4dλ, (4)
where k2 = 23 is the orientational factor assuming random orientation of the dyes, n is the refraction
index of the medium, ID(λ) is the fluorescence spectrum of the donor normalized so that
∫ ∞
0 ID(λ)dλ = 1,
and εA(λ) is the molar absorption coefficient of the acceptor. Φ0D, the fluorescence quantum yield of the
donor in the absence of energy transfer, was determined by the standard method (Equation (5)) [31,32],
Φ0D =
ArFDn2D
ADFrn2r
Φr, (5)
where A is the absorbance at the excitation wavelength, F the integrated emission area and n the
refraction index of the solvents used. Subscripts refer to the reference (r) or donor (D). The absorbance at
the excitation wavelength was always lower than 0.1 to avoid the inner filter effects. The NBD-C12-HPC
molecule intercalated in lipid membranes was used as reference, Φr = 0.32 at 25 ◦C, as reported by
Invitrogen [33].
The hydrophobic dyes curcumin (energy donor) and Nile Red (energy acceptor) (Figure 3) were
also incorporated in magnetoliposomes for monitoring the interaction of magnetoliposomes with giant
unilamellar vesicles (GUVs) by FRET.
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2.4.3. Fluorescence Anisotropy Measurements
The steady-state fluorescence anisotropy, r, is calculated by
r =
IVV −GIVH
IVV + 2GIVH
, (6)
where IVV and IVH are the intensities of the emission spectra obtained with vertical and horizontal
polarization, respectively (for vertically polarized excitation light), and G = IHV/IHH is the instrument
correction factor, where IHV and IHH are the emission intensities obtained with vertical and horizontal
polarization (for horizontally polarized excitation light).
2.4.4. Drug Encapsulation Efficiency
The encapsulation efficiency, EE(%), of the potential antitumor drugs in magnetoliposomes, was
determined through fluorescence emission measurements. For that, drug loaded magnetoliposomes
were subjected to centrifugation at 11,000 rpm for 60 min using Amicon® Ultra centrifugal filter units
100 kDa (Merck Millipore, Darmstadt, Germany). Then, the filtrate (containing the non-encapsulated
drug) was pipetted out, the water was evaporated and the same amount of ethanol was added. After
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vigorous agitation, its fluorescence was measured, allowing to determine the drug concentration using
a calibration curve (fluorescence intensity vs. concentration) previously obtained in the same solvent.
Three independent measurements were performed for each system and standard deviations (SD) were
calculated. The encapsulation efficiency was determined using Equation (7),
EE(%) =
(total amount− amount o f non encapsulated compound)
total amount
× 100 (7)
2.5. Structural Characterization
2.5.1. Electron Microscopy (TEM and SEM)
HR-TEM images of magnetic nanoparticles were recorded using a Transmission Electron
Microscope JEOL JEM 2010F (JEOL Ltd., Tokyo, Japan) operating at 200 kV coupled to an Electron
Dispersive Spectroscopic analyzer (EDS) at C.A.C.T.I (Centro de Apoio Científico e Tecnolóxico á
Investigación), Vigo, Spain. SEM images of solid magnetoliposomes were recorded using a Scanning
Electron Microscope FEI—Nova 200 NanoSEM (FEI Technologies, Inc., Hillsboro, OR, USA), operating
in transmission mode (STEM). For SMLs, a negative staining was employed, using a 2% aqueous
solution of ammonium molybdate tetrahydrate. 20 µL of sample and 20 µL of staining solution were
mixed and a drop of the mixture was placed onto a Formvar grid (Agar Scientific Ltd, Essex, UK), held
by tweezers. After 20 s, almost all the solution was removed with filter paper and left dry. TEM images
were processed using ImageJ software (National Institutes of Health (NIH), Bethesda, MD, USA) [34].
The area of each particle allowed an estimation of the particle diameter. The resulting histogram was
fitted to a Gaussian distribution.
2.5.2. X-Ray Diffraction (XRD)
X-ray diffraction (XRD) analyses were performed using a conventional Philips PW 1710
(Royal Philips, Amsterdam, The Netherlands) diffractometer, operating with Cu Kα radiation, in a
Bragg-Brentano configuration.
2.5.3. Dynamic Light Scattering (DLS)
The mean diameter and size distribution (polydispersity index) of aqueous and solid
magnetoliposomes (1 mM lipid concentration) were measured using a dynamic light scattering
(DLS) equipment NANO ZS Malvern Zetasizer (Malvern Panalytical Ltd., Malvern, UK) at 25 ◦C, using
a He-Ne laser of λ = 632.8 nm and a detector angle of 173◦. Five independent measurements were
performed for each sample.
2.6. Magnetic Measurements
Magnetization measurements were done in a MPMS3 SQUID magnetometer MPMS5XL (Quantum
Design Inc., San Diego, CA, USA). The hysteresis cycles (magnetization versus magnetic field) of the
samples were measured in the convenient field range for each sample. The measurement method was
by DC extraction or VSM oscillation at a frequency of 14 Hz. A specific magnetic field correction for the
trapped flux in the superconducting coil was made achieving an accuracy of residual less than 2 Oe.
2.7. Nanoparticles Encapsulation Efficiency
The nanoparticles encapsulation efficiency in aqueous magnetoliposomes (AMLs) was estimated
from the spectrophotometric determination of iron (III) content, through the formation of
a phenylfluorone complex sensitized with Triton X-100 [35]. To obtain iron (III) from the
magnetoliposomes, the latter were digested by heating at 500 ◦C overnight, to remove all the
biological components. Then, 1 mL of concentrated nitric acid (from Sigma-Aldrich) was added and
the sample was heated to 80 ◦C for 2 h. The temperature was then raised to 150 ◦C for 48 h, and the pH
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was increased until 5.5 by successive cycles of addition and evaporation of ultrapure water (Milli-Q
grade). Finally, 1 mL of water was added to the digested sample and, after ultrasonication for one
hour, the iron (III) content of magnetoliposomes was released.
For the spectrophotometric measurements, the standard addition method was employed. 100 µL
of the digested sample and 2 × 10−5 M, 3 × 10−5 M, 4 × 10−5 M, 5 × 10−5 M, or 6 × 10−5 M of iron (III)
stock solution were added to 1.6 × 10−4 M phenylfluorone and 4 × 10−3 M Triton X-100 solutions. The
pH was then adjusted to 9 using 0.05 M borax buffer [35]. A calibration curve for the determination of
iron (III) concentration was previously obtained. Three independent measurements were performed
and standard deviations (SD) were calculated. The encapsulation efficiency, EE(%), of calcium ferrite
nanoparticles (NPs) in AMLs was determined by equation:
EE(%) =
(total amount o f NPs− amount o f nonencapsulated NPs)
total amount o f NPs
× 100 (8)
2.8. Studies in Cell Lines
Compound 1 and compound 2 were tested in several cell lines, using different compound
concentrations (0.03 to 125 µM). In vitro cytotoxicity evaluation was assessed for four human tumor
cell lines, namely NCI-H460 (non-small cell lung cancer), HeLa (cervical carcinoma), and HepG2
(hepatic cancer). The cell line PLP2 (non-tumor cells) was used to evaluate the toxicity to healthy
tissues. The cells were routinely maintained as adherent cell cultures in RPMI-1640 medium containing
10% heat-inactivated FBS, at 37 ◦C, in a humidified air incubator containing 5% CO2. Each cell line
was plated at an appropriate density (1.0 × 104 cells per well) in 96-well plates and allowed to attach
for 24 h. The cells were then treated for 48 h with the different solutions. Following this incubation
period, the adherent cells were fixed by adding cold 10% TCA (100 µL) and incubated for 60 min at
4 ◦C. Plates were then washed with deionized water and dried. A sulforhodamine B (SRB) solution
(0.1% in 1% acetic acid, 100 µL) was then added to each plate-well and incubated for 30 min at room
temperature. Unbound SRB was removed by washing with 1% acetic acid. The plates were air-dried
and the bound SRB was solubilized with 10 mM Tris-HCl buffer (200 µL, pH = 7.4). The absorbance
was then measured at 540 nm in a microplate reader [36,37]. The results were expressed in GI50 values
(concentration that inhibited 50% of net cell growth).
Drug-loaded aqueous and solid magnetoliposomes were preliminary tested against breast cancer
cell lines, namely MCF-7 and MDA-MB-231.
3. Results and Discussion
3.1. Properties of the Antitumor Compounds
3.1.1. Studies in Cell Lines
Studies of the growth inhibitory activity in human tumor cell lines were performed to get a
deeper understanding of the antitumor capabilities of compounds 1 and 2. The assays were carried
out for NCI-H460 (non-small cell lung cancer), HeLa (cervical carcinoma) and HepG2 (hepatocellular
carcinoma). Assays using the non-tumor cell line PLP2 (porcine liver primary cells) were also performed
to evaluate compound toxicity to healthy tissues (Table 2).
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Table 2. Growth inhibitory concentrations (GI50) of compounds 1 and 2 in tumor cell lines and normal
(non-tumor) PLP2 cells.
GI50 (µM) a Compound 1 Compound 2
NCI-H460 34.6 ± 1.0 30.4 ± 1.3
HeLa 13.7 ± 0.6 13.0 ± 0.7
HepG2 25.4 ± 2.5 24.2 ± 1.5
PLP2 34.2 ± 3.3 46.8 ± 2.1
a GI50 values correspond to the concentration which inhibited 50% of cell growth. Results are from three independent
experiments (performed in triplicate), and are expressed as mean ± standard deviation (SD).
The results on Table 2 clearly show that both compounds are non-toxic for normal (non-tumor)
cells (PLP2), as the GI50 values are generally much higher than in human tumor cell lines. Besides, the
compounds show a notable specificity for breast cancer, exhibiting very low inhibitory concentrations
in MCF-7 breast adenocarcinoma cells (Table 1) and also in the highly aggressive, invasive and poorly
differentiated triple-negative breast cancer (MDA-MB-231 cell line) [24]. Compound 2 is slightly less
active in breast cancer cell lines (Table 1), but more active in the other tumor cell lines, being also less
toxic to non-tumor cells (Table 2). Therefore, the in vitro studies of cell inhibitory activity point to a
potential efficacy of these thienopyridine derivatives in oncological therapies focusing breast cancer.
3.1.2. Fluorescence Properties
Both compounds 1 and 2 exhibit fluorescence emission in several solvents but not in water, which
is a common behavior to other thienopyridine derivatives [38]. However, these compounds display
significant fluorescence when entrapped in liposomes, pointing to their location mainly in the lipid
bilayer [38]. Figure 4 shows the fluorescence spectra of antitumor compounds 1 and 2 in neat liposomes,
as well as examples of absorption spectra.
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Figure 4. Fluorescence spectra (λexc = 270 nm) of compound 1 (left) and compound 2 (right) in liposomes
of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and l-α-phosphatidylcholine from egg yolk
(Egg-PC), with compound concentration 5 × 10−6 M (T = 25 ◦C). Insets: Examples of absorption spectra
(compound concentration: 1 × 10−5 M).
The emission spectra of both compounds show some sensitivity to the environment felt by the
compound in liposomes, especially compound 2. In DPPC liposomes, which are in the gel phase at
room temperature, the thienopyridines may be located near the lipid polar head groups, feeling a
more hydrated environment than in Egg-PC liposomes, which are in the fluid phase (with a deeper
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penetration in the bilayer of the latter). This behavior allows the use of fluorescence emission to
investigate compounds location in magnetoliposomes and to determine the encapsulation efficiency in
these nanocarriers.
3.2. Nanoparticles Characterization
As referred, the interest in calcium ferrite nanoparticles is the substitution of transition metals
(Ni, Mn, Co . . . ) in ferrite nanoparticles, due to the toxicity of these elements. No doubt, iron oxide
nanoparticles have been the most widely used magnetic nanoparticles in biomedical applications
and are considered biocompatible. Compound 1 was even preliminary tested in magnetoliposomes
containing magnetite nanoparticles, in a previous work [39]. However, it has been reported that
these nanoparticles induce the production of reactive oxygen species (ROS) in mammalian cells [40],
causing severe DNA and protein damage and inflammatory responses, which may be a safety
concern [40–42]. Therefore, the development of magnetoliposomes containing other biocompatible
magnetic nanoparticles that may avoid these adverse effects is advantageous. In this respect, CaFe2O4
is a very attracting magnetic material because of its thermal and chemical stability, as well as the proven
high biocompatibility [8]. Considering all these aspects, in this work, calcium ferrite nanoparticles were
chosen for the preparation of magnetoliposomes, with the aim of a future application in cancer therapy.
3.2.1. Absorption Spectra
Figure 5 displays the UV/Visible absorption spectrum of the synthesized calcium ferrite
nanoparticles, exhibiting a wide wavelength range of absorption. Using a Tauc plot (Equation
(9)),
(αhν)n ∝
(
hν− Eg
)
, (9)
where α is the absorption coefficient (proportional to the absorbance), n is an exponent that depends
on the nature of the transition (being n = 2 for a direct semiconductor and n = 1/2 for an indirect one)
and Eg is the optical band gap [43], a linear relation was obtained for n = 2 (direct semiconductor). A
band gap of 2.19 eV was estimated from the intercept of inset of Figure 5, in agreement with the value
of 1.90 eV reported by Kim et al. [44].
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lines. This yielded a very good fit, with a RF value of 2.90 (Table 3). The resulting background 
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from the experimental XRD data. The resulting diffractogram was then analyzed using a much 
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method, as implemented by FullProf [45], the resulting average size was 5.4 nm. The lattice 
parameter is in accordance with values already reported for CaFe2O4 spinel structure, which are 
between 8.33 Å and 8.37 Å using a sol-gel combustion method [46,47], and 8.37 Å using a 
coprecipitation protocol [9]. 
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For the objectives of this work, the important feature is the wide absorption range of CaFe2O4
nanoparticles, which may quench drugs fluorescence emission in drug-loaded magnetoliposomes, as
previously described [19,21].
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3.2.2. X-Ray Diffraction (XRD) Measurements
The XRD diffractogram of the prepared calcium ferrite nanoparticles shows low intensity peaks
with large width characteristic of small crystalline nanoparticles (Figure 6A). The baseline is composed
of broad bands indicating the presence of amorphous content. Using FullProf software suite [45], the
diffractogram was fitted to a cubic spinel phase (space group Fd3m, adapted from magnetite CIF
9000926), with a degree of inversion i = 0.85, as reported by Lal et al. [46] and using, as background,
a set of 22 equally spaced points with adjustable intensities joined by linear regression lines. This
yielded a very good fit, with a RF value of 2.90 (Table 3). The resulting background (dashed line in
Figure 6A) was then fitted to a minimal set of Gaussian functions and subtracted from the experimental
XRD data. The resulting diffractogram was then analyzed using a much reduced set of 3 background
points (Figure 6B). A reasonable value of RF = 4.2 was obtained, confirming the synthesis of a pure
crystalline phase of calcium ferrite nanoparticles, since all their characteristic peaks, marked by their
indices, are observed (Figure 6B). Using the Debye-Scherrer method, as implemented by FullProf [45],
the resulting average size was 5.4 nm. The lattice parameter is in accordance with values already
reported for CaFe2O4 spinel structure, which are between 8.33 Å and 8.37 Å using a sol-gel combustion
method [46,47], and 8.37 Å using a coprecipitation protocol [9].Pharmaceutics 2019, 11, 477 11 of 21 
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Figure 6. XRD diffractogram of calcium ferrite nanoparticles. (A) Original; (B) Background subtracted.
Table 3. Selected Rietveld analysis parameters.
Sample Ox,y,z i *
L ttice
Constant
(nm)
Size (nm) RF χ2
CaFe2O4 (original
XRD data) 0.243 0.85 0.8340 4.83 2.90 1.06
2 4 (background
subtracted XRD data) 0.241 0.85 0.8338 5.26 4.98 0.91
* fixed value.
3.2.3. Transmission Electron Microscopy (TEM)
TEM images (Figure 7A) of the CaFe2O4 prepared nanoparticles reveal cuboid/spherical
nanoparticles with line patterns that arise from electron beam diffraction at crystal planes. The
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limits of these patterns helped on the identification of individual particles, as shown by the green lines
in Figure 7A. The shown histogram results from the area of 71 nanoparticles and is well described by a
Gaussian distribution of 5.2 ± 1.2 nm. This is in excellent agreement with the XRD results. Figure 7B is
the fast Fourier transform (FFT) of Figure 7A, using ImageJ image processing software. The bright spots
allowed identifying a set of d-spacing values that, using a cubic fcc crystal structure (Equation (10)),
are compatible with a lattice constant a = 8.37 Å and Miller indices (h k l) = (1 1 0), (1 1 1), (2 0 0), (1 2 0),
(2 1 1), (2 2 0), (2 2 1), (2 2 2), (3 2 0), and (3 2 1).
dhkl =
a√
h2 + k2 + l2
(10)
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These results are again in agreement with the previous XRD analysis of the obtained CaFe2O4
nanoparticles. A further confirmation of the identity of the nanoparticles observed in TEM images was
achieved from EDX measurements (Figure 7D–F). It is clearly observed that most of the particles in
Figure 7C have simultaneously Ca, Fe, and O atoms, thus being compatible with the expected calcium
ferrite phase.
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3.2.4. Magnetic Properties
The magnetic properties of CaFe2O4 nanoparticles were characterized by their magnetic hysteresis
loop, obtained using a SQUID magnetometer, where the relation between the induced magnetic moment
(M) and the applied magnetic field (H) is evidenced. The M-H curve at room temperature is plotted in
Figure 8. From the hysteresis loop, a slight coercivity (Hc) of 3.41 Oe and a low remanent magnetization
(Mr) of 0.06 emu/g were determined, pointing to a superparamagnetic behavior. Superparamagnetism
can be related to the magnetic squareness value of the hysteresis cycle, which is the ratio between the
remanescent magnetizations and the saturation magnetization (Ms). If below 0.1, this ratio indicates that
more than 90% of the magnetization is lost upon the removal of the applied magnetic field [48,49]. Here,
the obtained magnetic squareness value of 0.005 (using the maximum magnetization of 12.81 emu/g at
H = 70 kOe) clearly indicates that the synthesized CaFe2O4 nanoparticles are superparamagnetic at
room temperature. Saturation in magnetization was not achieved at the maximum applied field of
70 kOe, which can be due to non collinear canted magnetic structure (typical of small nanoparticles
with high surface-to-volume ratio).Pharmaceutics 2019, 11, 477 13 of 21 
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(T = 300 K). Inset: Enlargement of the loop in the low field region.
As used in the analysis of XRD results, the obtained CaFe2O4 nanoparticles have a strongly
inverted spinel structure, with an inversion degree of 0.85. Therefore, its lattice can be written as (Ca0.15
Fe0.85↑) [Ca0.85 Fe1.15↓]O4, where parentheses depict the cations at the tetrahedral sites and square
brackets the amount of cations at octahedral ones. Lal et al. [46] have computed an expected magnetic
moment per unit formula of 1.78 µB for CaFe2O4 nanoparticles with the same lattice structure. Here,
a value of 0.49 µB is obtained through the relation ηB = (MW ×Ms)/5585 (where ηB is the magnetic
moment in Bohr units and MW is the molecular weight) [49,50]. The difference between this estimation
and the computed value of magnetic moment [46] can be attributed to the spin canting phenomenon
typical of this type of ferrites [49–51] and to the amorphous content of the prepared nanoparticles (as
evidenced from the XRD data).
The maximum magnetization of calcium ferrite nanoparticles is slightly lower than the one
previously obtained for magnesium ferrite nanoparticles also prepared by coprecipitation [21],
however keeping the superparamagnetic character. Despite the low maximum magnetization, these
nanoparticles guarantee enhanced biocompatibility [8] and superparamagnetic characteristics, avoiding
the undesirable oxidation and production of reactive oxygen species (ROS) in mammalian cells by iron
oxide nanoparticles that cause DNA and protein damage and inflammatory responses [40,41,52].
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3.3. Development of Magnetoliposomes
The obtained magnetic nanoparticles were either entrapped in liposomes (aqueous
magnetoliposomes, AMLs) or covered by a lipid bilayer, forming solid magnetoliposomes (SMLs). As
previously reported, solid magnetoliposomes are only suitable as carriers for hydrophobic drugs, but
exhibit magnetic properties similar to those of the neat nanoparticles. On the other hand, aqueous
magnetoliposomes can be used as nanocarriers for both hydrophilic and hydrophobic drugs, but their
magnetic properties are poorer, due to the diamagnetic contribution of water [26,27].
3.3.1. Magnetoliposomes Characterization
The calcium ferrite nanoparticles were entrapped in liposomes composed either by the
phospholipid Egg-PC or DPPC. The hydrodynamic diameter and polydispersity (PDI) of these
aqueous magnetoliposomes were determined by DLS (Table 4).
Table 4. Size and polydispersity of solid and aqueous magnetoliposomes determined by dynamic light
scattering (DLS) (SD: standard deviation).
System Lipid Size ± SD (nm) PDI ± SD
AMLs
Egg-PC 129 ± 12 0.139 ± 0.04
DPPC 132 ± 15 0.185 ± 0.08
SMLs DPPC 164 ± 23 0.203 ± 0.02
The nanoparticles encapsulation efficiency in aqueous Egg-PC liposomes was calculated from the
spectrophotometric determination of iron (III) [35]. The encapsulation efficiency, EE(%), obtained from
three independent assays, was EE(%) ± SD(%) = 70.(4) ± 9. This percentage is slightly higher than the
one reported for magnetite nanoparticles using the same encapsulation method [39].
Considering solid magnetoliposomes, the phospholipid DPPC was chosen, due to its melting
transition temperature (41 ◦C [53]) is near mild hyperthermia temperatures [54]. At this transition
temperature, the bilayer liquid-crystalline phase is attained, with an increase in membrane permeability,
enhancing drug release into cell membranes. Therefore, a local temperature rise promoted by the
magnetic nanoparticles under an alternating magnetic field (AMF) can trigger drug release.
The values of hydrodynamic diameter determined by DLS are similar to those previously
reported [21,39,55] for magnetoliposomes of the same lipids (and containing different nanoparticles),
evidencing that small magnetic nanoparticles does not influence the magnetoliposomes size. The
polydispersity index (PDI) is generally low and point to systems that are monodisperse in size. The
diameter of magnetoliposomes must be small to guarantee an enhanced permeability and retention
(EPR) effect of loaded drugs. The successful extravasation into tumors has been shown to occur for
nanocarriers with sizes below 200 nm [56], which is the case of the nanosystems developed here.
Considering solid magnetoliposomes (SMLs), calcium ferrite nanoparticles are being used for
the first time to synthesize this type of magnetoliposomes. It is, therefore, important to prove that a
lipid bilayer is formed around a cluster of these magnetic nanoparticles. This can be done using FRET
assays, where the labeled lipid NBD-C12-HPC (NBD as the energy donor, Figure 2) was included in
the first lipid layer of SMLs and the lipid Rhodamine B-DOPE (rhodamine B as the acceptor, Figure 2)
was included in the second lipid layer. The emission of SMLs containing only the NBD-labeled lipid
and SMLs containing both donor and acceptor labeled lipids were measured (Figure 9A), exciting only
the donor NBD. The fluorescence spectrum of SMLs with only the donor exhibits the NBD emission
band (λmax = 535 nm), while the spectra of SMLs containing both donor and acceptor reveals a strong
decrease in the NDB emission and the notable appearance of rhodamine B band, evidencing the
occurrence of energy transfer from the excited NBD moiety to Rhodamine B. A FRET efficiency of 0.723
was estimated (using Equations (2)–(5)), corresponding to a donor-acceptor distance of 3.8 nm. These
distance values prove the formation of the double lipid layer in SMLs, taking into account the usual
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cell membrane thickness, varying from 7 to 9 nm [57]. SEM images of these SMLs (Figure 9B) show
roughly spherical structures containing nanoparticles aggregates, with sizes slightly around 170 nm, in
accordance with those determined by DLS.
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Figure 9. (A) Fluorescence spectra (λexc = 470 nm, no rhodamine excitation) of solid magnetoliposomes
(SMLs) labelled with only NBD-C12-HPC and labeled with both NBD-C12-HPC and rhodamine B-DOPE;
(B) SEM image (scale bar: 200 nm) of an aggregate of two SMLs containing CaFe2O4 nanoparticles
(obtained with a negative staining).
3.3.2. Interaction with Model Membranes
For drug delivery purposes, it is also important that magnetoliposomes have some fusogenic
capability with the cell membranes. This was assessed by investigating the non-specific interaction
with giant unilamellar vesicles (GUVs), used as membrane models. This investigation was carried
out using FRET (Förster resonance energy transfer) assays, where the aqueous magnetoliposomes
(AMLs) containing two hydrophobic dyes, curcumin (acting as the energy donor, Figure 3) and Nile
Red (as the energy acceptor, Figure 3), were prepared. Curcumin is a highly hydrophobic fluorescent
compound [58], being located in the lipid bilayer of liposomes [21]. On the other hand, Nile Red
has been widely used as lipid probe [59–61], the pair curcumin/Nile Red being a very favorable
donor–acceptor pair in FRET assays [21]. Exciting only the donor curcumin, a strong fluorescence
band due to Nile Red emission is observed (with maximum wavelength around 630 nm), resulting
from energy transfer from curcumin to Nile Red (Figure 10A). After interaction with GUVs, the donor
fluorescence (λmax ~ 500 nm) increases and the acceptor emission band decreases, evidencing the
diminution of FRET process efficiency and, consequently, proving the membrane fusion between AMLs
and GUVs.
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Figure 10. (A). Fluorescence spectra (λexc = 440 nm) of aqueous magnetoliposomes (AMLs) of CaFe2O4
nanoparticles conta ning both curcumin (2 × 10−6 M) and Nile Red (2 × 10−6 M), before and after
interaction with GUVs. (B) Fluore cence spectra (λexc = 470 nm) of SMLs of CaFe2O4 nanoparticles
containing NBD-C12-HPC (3 × 10−6 M) before and after interactio with GUVs.
For SMLs, as previously described [19–21], FRET process is usually not observed due to the strong
quenching of both donor and acceptor emissions by the cluster of magnetic nanoparticles. Instead,
the lipid bilayer of SMLs was labeled with only a fluorescent lipid, NBD-C12-HPC (Figure 2). Upon
interaction with GUVs, a significant rise in NBD fluorescence is observed (unquenching effect), proving
the increase in the distance between the nanoparticles and the fluorescent moiety (NBD, λmax = 535 nm),
and thus membrane fusion occurs (Figure 10B).
3.4. Drug-Loaded Magnetoliposomes
The antitumor comp unds 1 and 2 were incorporated in both aqueous and solid magnetoliposomes.
The two compounds exhibit fluorescence in these nanocarriers, indicating that they must be located
in the lipid bilayer (as they are non-emissive in aqueous media). An emission quenching by the
nanoparticles is observed for these thienopyridine derivatives, more significant in SMLs, where
the cluster of nanoparticles is closer to the antitumor compound (comparing to the case of AMLs)
(Figure 11). A similar behavior was previously observed for other antitumor drugs [19,21] and for
compound 1 in magnetoliposomes containing iron oxide nanoparticles [39].
Pharmaceutics 2019, 11, 477 16 of 21 
 
 
Figure 11. Fluorescence spectra of antitumor compound 2 in liposomes, AMLs and SMLs. 
Fluorescence anisotropy measurements of both compounds (Table 5) were determined in 
liposomes (without the magnetic nanoparticles), in AMLs and in SMLs. The values in glycerol are 
presented for comparison, as in this highly viscous medium (η = 993.4 cP at room temperature [62]), 
compound molecules rotate slowly and anisotropy value approaches the fundamental anisotropy 
[30]. From the anisotropy results, one can observe that the values in liposomes are similar to the 
ones in AMLs and SMLs, pointing to the compound location in the lipid membrane in all the 
nanocarriers. This is not surprising, as these compounds are hydrophobic molecules. Moreover, a 
decrease in anisotropy is observed for DPPC at 55 °C, where the lipid bilayer is in the 
liquid-crystalline phase. This indicates that compounds are experiencing a higher degree of rotation 
in this case, with a consequent decrease in fluorescence anisotropy. Also, in phosphatidylcholine 
from egg yolk (Egg-PC), which is a phosphatidylcholine mixture with some unsaturated lipid 
chains (main components are 16:0 PC, 18:0 PC, and 18:1 PC), the anisotropy values are lower than in 
DPPC (16:0 PC) at room temperature, signifying larger freedom for the antitumor drugs in Egg-PC. 
Table 5. Steady-state fluorescence anisotropy (r) values for the antitumor compounds 1 and 2 in 
magnetoliposomes and comparison with the values in neat liposomes. 
  Lipid 
Anisotropy, r  
Compound 1 Compound 2 
Liposomes 
Egg-PC (25 °C)     0.182 [39] 0.155 
DPPC (25 °C)     0.251 [39] 0.181 
DPPC (55 °C)     0.157 [39] 0.115 
AMLs 
Egg-PC (25 °C) 0.176 0.138 
DPPC (25 °C) 0.232 0.189 
DPPC (55 °C) 0.106 0.105 
SMLs DPPC (25 °C) 0.212 0.175 DPPC (55 °C) 0.094 0.106 
Glycerol ----     0.308 [39] 0.255 
The drug encapsulation efficiencies were determined for both antitumor compounds in 
AMLs and SMLs (Table 6). The encapsulation efficiency is higher for aqueous 
magnetoliposomes, compound 2 being the one exhibiting greater percentages. Nevertheless, 
in solid magnetoliposomes, the encapsulation efficiencies are still very reasonable. Generally, 
the high EE% obtained point to a promising future utility of the drug-loaded nanocarriers 
containing biocompatible calcium ferrite nanoparticles in cancer therapeutics, specifically for 
breast cancer therapy. 
  
Figure 11. Fluorescence spectra of antitumor compound 2 in liposomes, AMLs and SMLs.
Fluorescence anisotropy measurements of both compounds (Table 5) were determined in liposomes
(without the magnetic nanoparticles), in AMLs and in SMLs. The values in glycerol are presented for
comparison, as in this highly viscous medium (η = 993.4 cP at room temperature [62]), compound
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molecules rotate slowly and anisotropy value approaches the fundamental anisotropy [30]. From
the anisotropy results, one can observe that the values in liposomes are similar to the ones in AMLs
and SMLs, pointing to the compound location in the lipid membrane in all the nanocarriers. This is
not surprising, as these compounds are hydrophobic molecules. Moreover, a decrease in anisotropy
is observed for DPPC at 55 ◦C, where the lipid bilayer is in the liquid-crystalline phase. This
indicates that compounds are experiencing a higher degree of rotation in this case, with a consequent
decrease in fluorescence anisotropy. Also, in phosphatidylcholine from egg yolk (Egg-PC), which is
a phosphatidylcholine mixture with some unsaturated lipid chains (main components are 16:0 PC,
18:0 PC, and 18:1 PC), the anisotropy values are lower than in DPPC (16:0 PC) at room temperature,
signifying larger freedom for the antitumor drugs in Egg-PC.
Table 5. Steady-state fluorescence anisotropy (r) values for the antitumor compounds 1 and 2 in
magnetoliposomes and comparison with the values in neat liposomes.
Lipid Anisotropy, r
Compound 1 Compound 2
Liposomes
Egg-PC (25 ◦C) 0.182 [39] 0.155
DPPC (25 ◦C) 0.251 [39] 0.181
DPPC (55 ◦C) 0.157 [39] 0.115
AMLs
Egg-PC (25 ◦C) 0.176 0.138
DPPC (25 ◦C) 0.232 0.189
DPPC (55 ◦C) 0.106 0.105
SMLs
DPPC (25 ◦C) 0.212 0.175
DPPC (55 ◦C) 0.094 0.106
Glycerol —- 0.308 [39] 0.255
The drug encapsulation efficiencies were determined for both antitumor compounds in AMLs
and SMLs (Table 6). The encapsulation efficiency is higher for aqueous magnetoliposomes, compound
2 being the one exhibiting greater percentages. Nevertheless, in solid magnetoliposomes, the
encapsulation efficiencies are still very reasonable. Generally, the high EE% obtained point to a
promising future utility of the drug-loaded nanocarriers containing biocompatible calcium ferrite
nanoparticles in cancer therapeutics, specifically for breast cancer therapy.
Table 6. Encapsulation efficiencies of antitumor compounds 1 and 2 in both AMLs and SMLs.
System EE% ± SD
Compound 1 Compound 2
AMLs (Egg-PC) 81.9 ± 8.5 86.3 ± 8.2
SMLs (DPPC) 68.2 ± 9.1 75.8 ± 10.9
Preliminary assays using drug-loaded magnetoliposomes (AMLs and SMLs) in breast cancer cell
lines, MCF-7 and MDA-MB-231, were performed (Figure 12). Free (non-encapsulated) drugs were
already tested in previous publications [23,24], using the same human breast cancer cell lines, with the
determination of GI50 values [24] (values indicated in Table 1).
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Figure 12. Viability of breast cancer cells MCF-7 and MDA-MB-231 in presence of drug-loaded aqueous
(AMLs) and solid (SMLs) magnetoliposomes for compound 1 (above) and compound 2 (below). GI50
values of free drugs in breast cancer cells: MCF-7—Compound 1: (1.2 ± 0.2) × 10−6 M, Compound 2:
(1.6 ± 0.3) × 10−6 M; MDA-MB-231—Compound 1: (5.0 ± 0.7) × 10−6 M, Compound 2: (7.0 ± 0.8) ×
10−6 M.
Figure 12 shows a generally low inhibitory activity of cells for all formulations, indicating a
lack of toxicity of the drug-loaded magnetoliposomes in the absence of an alternating magnetic field
(AMF). The most significant activity was observed for SMLs loaded with compound 1 in MCF-7 cell
line, yet, no cytotoxicity was observed, but only a reduced cell viability. Typically, encapsulated
drugs present lower bioavailability when compared to free drugs and, therefore, less cytotoxicity is
observed for encapsulated drugs. In both solid and aqueous magnetoliposomes, compounds 1 and 2
remain encapsulated for more than two days (in the conditions used in cell culture) and no release is
observed to the surrounding medium, which was expected considering the hydrophobic nature of the
compounds. So, these assays prove that drug-loaded magnetoliposomes have practically absence of
toxicity, which makes them advantageous systems for triggered drug release by application of an AMF
to promote local heating, that increases liposomes membrane fluidity. Therefore, in future work, the
drug-loaded magnetoliposomes (without the application of AMF) will act as a control. The results
obtained here are promising for future applications, by showing that these systems only release the
loaded cargo upon the application of an alternating magnetic field, that causes a local heating effect
(hyperthermia), also synergistically inducing cell death.
4. Conclusions
In this work, both aqueous and solid magnetoliposomes containing calcium ferrite nanoparticles
were developed. The nanosystems obtained, with sizes below or around 170 nm, revealed to be
promising as nanocarriers for two new thienopyridine-based anticancer drugs active against breast
cancer (including the highly aggressive MDA-MB-231 cells). Solid and aqueous magnetoliposomes were
able to interact with model membranes (GUVs) by fusion. Considering the high drug encapsulation
efficiencies, the lack of toxicity of the drug-loaded systems and the selective antitumor activity of both
compounds, the drug-loaded magnetoliposomes containing CaFe2O4 nanoparticles are promising
Pharmaceutics 2019, 11, 477 18 of 21
to future applications in dual therapy (combining magnetic-triggered chemotherapy and magnetic
hyperthermia) for breast cancer.
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